Autonomous Regulatory Monocytes (OPM Cells) for the Treatment of Diabetic Foot in a Single-arm Open-label Clinical Study

The trial is designed to last up to 26 weeks, including a screening period of 1 week, a treatment period of 1 week, and an observation period of 24 weeks. According to the inclusion criteria, 10 diabetic patients with ulcers will be clinically screened, and after signing the informed consent form, they will be assigned a number. Post-injection of OPM cells, wound assessments are conducted weekly, with physical examinations and vital signs (pulse, blood pressure) recorded at weeks 4, 8, 12, 16, 20, and 24. Clinical laboratory tests (routine blood tests, tumor markers, etc.) are performed at week 12. Vascular CTA and immune cell count in wound lavage fluid are conducted at week 24 post-cellular intervention, followed by a final examination at week 24.